ReviewMolecular neurobiology2009
The fragile X mental retardation protein in circadian rhythmicity and memory consolidation.
Review in Molecular neurobiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 37 citations in OpenAlex.
- Compensatory Regulation of Excitation/Inhibition Balance in the Ventral Hippocampus: Insights from Fragile X Syndrome.Biology · 2025Review
- Rescue of sharp wave-ripples and prevention of network hyperexcitability in the ventral but not the dorsal hippocampus of a rat model of fragile X syndrome.Frontiers in cellular neuroscience · 2023Article
- GABA Measurement in a Neonatal Fragile X Syndrome Mouse Model UsingFrontiers in molecular neuroscience · 2020Article
- Aberrant Proteostasis of BMAL1 Underlies Circadian Abnormalities in a Paradigmatic mTOR-opathy.Cell reports · 2017Article
- Neuron class-specific requirements for Fragile X Mental Retardation Protein in critical period development of calcium signaling in learning and memory circuitry.Neurobiology of disease · 2016Article
- Guardian of Genetic Messenger-RNA-Binding Proteins.Biomolecules · 2016Review
- A new look at an old drug: neuroprotective effects and therapeutic potentials of lithium salts.Neuropsychiatric disease and treatment · 2016Review
- Deciphering discord: How Drosophila research has enhanced our understanding of the importance of FMRP in different spatial and temporal contexts.Experimental neurology · 2015Review
- Glycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice.Biological psychiatry · 2014Article
- The translation of translational control by FMRP: therapeutic targets for FXS.Nature neuroscience · 2013Review
- Lithium treatment alleviates impaired cognition in a mouse model of fragile X syndrome.Genes, brain, and behavior · 2013Article
- Learning and memory deficits consequent to reduction of the fragile X mental retardation protein result from metabotropic glutamate receptor-mediated inhibition of cAMP signaling in Drosophila.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2012Article
- hnRNP Q regulates Cdc42-mediated neuronal morphogenesis.Molecular and cellular biology · 2012Article
- In vivo neuronal function of the fragile X mental retardation protein is regulated by phosphorylation.Human molecular genetics · 2012Article
- Matrix metalloproteinases and minocycline: therapeutic avenues for fragile X syndrome.Neural plasticity · 2012Review
- Drosophila modeling of heritable neurodevelopmental disorders.Current opinion in neurobiology · 2011Review
- Neural circuit architecture defects in a Drosophila model of Fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinase.Disease models & mechanisms · 2011Article
- Fragile X mental retardation protein is required for programmed cell death and clearance of developmentally-transient peptidergic neurons.Developmental biology · 2011Article
- Defects in translational regulation contributing to human cognitive and behavioral disease.Current opinion in genetics & development · 2011Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The control of new protein synthesis provides a means to locally regulate the availability of synaptic components necessary for dynamic neuronal processes. The fragile X mental retardation protein (FMRP), an RNA-binding translational regulator, is a key player mediating appropriate synaptic protein synthesis in response to neuronal activity levels. Loss of FMRP causes fragile X syndrome (FraX), the most commonly inherited form of mental retardation and autism spectrum disorders. FraX-associated translational dysregulation causes wide-ranging neurological deficits including severe impairments of biological rhythms, learning processes, and memory consolidation. Dysfunction in cytoskeletal regulation and synaptic scaffolding disrupts neuronal architecture and functional synaptic connectivity. The understanding of this devastating disease and the implementation of meaningful treatment strategies require a thorough exploration of the temporal and spatial requirements for FMRP in establishing and maintaining neural circuit function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.